12 November 2026
Santhera Pharmaceuticals CFO on AGAMREE growth in 2026 - One2One Investor Forum
Proactive - Interviews for investors
About
For the best viewing experience: This video is available in Full HD (1080p). YouTube may automatically select a lower resolution depending on your internet connection. To view the presentation clearly, click the Settings (:gear:) icon on the video, select Quality, and choose 1080p. On mobile, select Settings → Quality → Advanced → 1080p.
Santhera Pharmaceuticals CFO Catherine Isted talked with Proactive at the Proactive One2One Investor Forum about the company's commercial progress with AGAMREE, its treatment for Duchenne muscular dystrophy (DMD), alongside its H1 2026 financial performance, international expansion strategy and long-term revenue outlook.
Isted outlined Santhera's growing commercial presence across Europe, where AGAMREE is now generating sales in four of the five major markets following pricing and reimbursement agreements in Spain and Italy. The company reported a 50% increase in bottle volumes in Germany during H1 2026 compared with the corresponding period in 2025, while UK volumes increased 40% quarter on quarter in Q2 2026.
Financially, Santhera reported H1 2026 revenues of CHF 48.3 million, representing growth of more than 100%. Product sales increased by nearly 50%, supported by growing AGAMREE adoption and geographic expansion.
The company expects full-year 2026 revenues of CHF 80 million to CHF 90 million, with longer-term revenue guidance, excluding milestones, of CHF 140 million by 2028 and CHF 250 million by 2030.
#proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #SantheraPharmaceuticals #AGAMREE #DuchenneMuscularDystrophy #DMD #Biotech #Pharmaceuticals #BiotechInvesting #RareDiseases #HealthcareInvesting #FinancialResults #InvestorNews
Santhera Pharmaceuticals CFO Catherine Isted talked with Proactive at the Proactive One2One Investor Forum about the company's commercial progress with AGAMREE, its treatment for Duchenne muscular dystrophy (DMD), alongside its H1 2026 financial performance, international expansion strategy and long-term revenue outlook.
Isted outlined Santhera's growing commercial presence across Europe, where AGAMREE is now generating sales in four of the five major markets following pricing and reimbursement agreements in Spain and Italy. The company reported a 50% increase in bottle volumes in Germany during H1 2026 compared with the corresponding period in 2025, while UK volumes increased 40% quarter on quarter in Q2 2026.
Financially, Santhera reported H1 2026 revenues of CHF 48.3 million, representing growth of more than 100%. Product sales increased by nearly 50%, supported by growing AGAMREE adoption and geographic expansion.
The company expects full-year 2026 revenues of CHF 80 million to CHF 90 million, with longer-term revenue guidance, excluding milestones, of CHF 140 million by 2028 and CHF 250 million by 2030.
#proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #SantheraPharmaceuticals #AGAMREE #DuchenneMuscularDystrophy #DMD #Biotech #Pharmaceuticals #BiotechInvesting #RareDiseases #HealthcareInvesting #FinancialResults #InvestorNews